PMID- 19697097
OWN - NLM
STAT- MEDLINE
DCOM- 20100219
LR  - 20220331
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 19
IP  - 6
DP  - 2009
TI  - Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis 
      and rheumatoid arthritis.
PG  - 581-9
LID - 10.1007/s10165-009-0210-0 [doi]
AB  - Oral tolerance means a diminished immune response to previously fed antigens. 
      Repeated oral administrations of type II collagen (CII) induce oral tolerance and 
      inhibit the development of collagen-induced arthritis (CIA). Dendritic cells 
      (DCs) in the gut-associated lymphoid tissue (GALT) take up the CII and then 
      present it to T cells to generate regulatory T cells (Tregs), which induce 
      systemic immune tolerance to CII. Inhibitory cytokines, such as transforming 
      growth factor (TGF)-beta and interleukin (IL)-10, and several immune regulatory 
      molecules, including indoleamine 2,3-dioxygenase (IDO) and retinoic acid, play an 
      important role in Treg generation. Each DC subset may play different roles, and 
      CD11c+CD11b+DCs and IDO+DCs are important in the generation of antigen-inducible 
      Tregs in CII oral tolerance. Upon stimulation with the antigen involved in its 
      generation, Treg is activated and regulates the immune response through 
      inhibitory cytokine production, cell-to-cell contact-dependent mechanisms, DC 
      modification, and bystander suppression. The DCs and Tregs are deeply involved in 
      oral tolerance through reciprocal interactions. Several clinical trials have been 
      conducted in RA patients to examine the efficacy of CII oral tolerance. An 
      understanding the mechanism of oral tolerance to CII would give clinicians new 
      insights into the development of natural immune tolerance and new therapeutic 
      approaches for the treatment of autoimmune diseases.
FAU - Park, Kyung-Su
AU  - Park KS
AD  - Division of Rheumatology and Rheumatism Research Center, The Catholic University 
      of Korea, Seoul, Korea.
FAU - Park, Min-Jung
AU  - Park MJ
FAU - Cho, Mi-La
AU  - Cho ML
FAU - Kwok, Seung-Ki
AU  - Kwok SK
FAU - Ju, Ji Hyeon
AU  - Ju JH
FAU - Ko, Hyeok-Jae
AU  - Ko HJ
FAU - Park, Sung-Hwan
AU  - Park SH
FAU - Kim, Ho-Youn
AU  - Kim HY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090821
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Collagen Type II)
RN  - 0 (Cytokines)
SB  - IM
MH  - Administration, Oral
MH  - Arthritis, Experimental/chemically induced/*immunology
MH  - Arthritis, Rheumatoid/*immunology
MH  - Collagen Type II/administration & dosage/*immunology
MH  - Cytokines/immunology
MH  - Humans
MH  - Immune Tolerance/*immunology
MH  - T-Lymphocytes, Regulatory/immunology
RF  - 99
EDAT- 2009/08/22 09:00
MHDA- 2010/02/20 06:00
CRDT- 2009/08/22 09:00
PHST- 2009/05/29 00:00 [received]
PHST- 2009/07/08 00:00 [accepted]
PHST- 2009/08/22 09:00 [entrez]
PHST- 2009/08/22 09:00 [pubmed]
PHST- 2010/02/20 06:00 [medline]
AID - 10.1007/s10165-009-0210-0 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2009;19(6):581-9. doi: 10.1007/s10165-009-0210-0. Epub 2009 Aug 
      21.